Epicrispr positive trial and first use of AI twin
Epicrispr trial using Springbok AI twin shows positive clinical evidence of increased lean muscle, including results from an Australian site
Stay connected with the latest developments in FSHD research and community progress. This is your trusted hub for updates on scientific breakthroughs, inspiring personal stories, and the work we’re doing globally to accelerate treatments and a cure for Facioscapulohumeral Muscular Dystrophy (FSHD).
By staying informed and engaged, you’re helping us raise awareness, support individuals and families impacted by FSHD, and drive real momentum toward lasting solutions.
Epicrispr trial using Springbok AI twin shows positive clinical evidence of increased lean muscle, including results from an Australian site

This method improves sensitivity and helps broaden the definition of genetic FSHD to more accurately correspond to clinical FSHD, allowing identification of those at risk in affected families and in large population studies.
Encouraging news from the Avidity/Novartis trial using targeted siRNA to suppress DUX4 in FSHD. The therapy, del-brax, is an investigational
FSHD Global was pleased to join Muscular Dystrophy Queensland for a webinar covering the latest developments in FSHD research and
A review of the pioneering research that uses MRI scans and AI to enable clinical trials for FSH muscular dystrophy and other neuromuscular conditions.
Project Mercury was established in 2023 to address critical challenges for clinical trials – ensuring safe and effective treatments reach patients quickly, equitably, and at scale.
We publish a monthly newsletter to keep the FSHD community informed, connected, and inspired. If there’s a story you’d like to tell, a question you’d like answered, or a topic you think we should explore, we’d love to hear from you.
Send an email to admin@fshdglobal.org.